GMAB News and Press, Genmab A/S From 04/29/24

TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer Conversion to full approval from accelerated approval is based on positive results from global Phase 3 study demonstrating ...

2024-04-29 15:08:53 ET Summary AbbVie Inc.'s shares dropped last week due to concerns about the erosion of Humira and despite the company beating revenue and EPS expectations. Humira's global sales fell 36% YoY, but AbbVie's other growth products performed well, leading to overall...

2024-04-29 08:51:30 ET Summary Immatics N.V., a European T-Cell receptor therapy company, is expected to release clinical data on all four of its candidates in 2024. The company's main focus is on developing T-cell receptor therapies for the treatment of solid tumors. Immatics...

2024-04-16 11:20:38 ET Summary Genmab will acquire ProfoundBio for $1.8 billion in cash. The acquisition adds an important antibody drug conjugate ('ADC') platform, a missing piece in Genmab's platform. Genmab plans to advance ProfoundBio's lead candidate, Rina-S, to registrat...

2024-04-16 07:20:23 ET Reporting its Q1 2024 results, Big Pharma’s earnings bellwether, Johnson & Johnson ( NYSE: JNJ ), revised its full-year outlook below consensus on Tuesday after sales from its MedTech division fell short of Street forecasts.... Read the full a...

2024-04-08 15:15:00 ET Summary Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion. The deal is the fourth acquisition of a China-related innovative drugmaker by a foreign company in the last four months. The deal comes...

2024-04-07 06:30:00 ET Summary ProfoundBio, a Seattle ADC company with an R&D facility in Suzhou, will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. China Medical System in-licensed povorcitinib, an oral JAK1 inhibitor, from San Franciscoȁ...

2024-04-03 04:17:15 ET More on Genmab: Genmab: Recent Updates Support The Growth Narrative Genmab's Arbitration Loss: Best To Forgive And Forget (Rating Upgrade) Genmab announces ~$510M worth of share buybacks AbbVie/ Genmab win FDA priority review for lympho...

2024-04-02 01:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-23 00:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...